Transpl Int . Anti-HLA and anti-SARS-CoV2 Antibodies in Kidney Transplant Recipient with COVID-19

[tetano]

Transpl Int


. 2021 Jan 22.
doi: 10.1111/tri.13829. Online ahead of print.
Anti-HLA and anti-SARS-CoV2 Antibodies in Kidney Transplant Recipient with COVID-19


Ilaria Gandolfini ¹ , Paola Zanelli ² , Alessandra Palmisano ¹ , Daniel Salvetti ¹ , Alice Parmigiani ¹ , Jonathan S Maltzman ³ , Claudia Labate ² , Enrico Fiaccadori ¹ , Paolo Cravedi ⁴ , Umberto Maggiore ¹



Affiliations

• PMID: 33481306
• DOI: 10.1111/tri.13829

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and its associated illness coronavirus disease 2019 (COVID-19) have severely affected organ transplant recipients, with all-cause mortality rates exceeding 20% (1, 2). Although no clear guidelines exist on how to adjust immunosuppression, most centers reduce anti-rejection drugs to facilitate the T and B cell response against the virus.

Keywords: COVID-19; alloantibodies; donor-specific antibodies; kidney transplantation.